LB42708featured
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:406418
CAS#:226929-39-1
Description:LB42708 is a potent, orally active and selective nonpeptidic farnesyltransferase inhibitor (FTase inhibitor). LB42708 inhibited VEGF-induced Ras activation and subsequently suppressed angiogenesis in vitro and in vivo by blocking the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase/p38 mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt/endothelial nitric-oxide synthase pathways in endothelial cells without altering FAK/Src activation.
Price and Availability
LB42708, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS docum ents are available in one week after order is received.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 406418Name: LB42708CAS#: 226929-39-1Chemical Formula: C30H27BrN4O2Exact Mass: 554.13174Molecular Weight: 555.46Elemental Analysis: C, 64.87; H, 4.90; Br, 14.39; N, 10.09; O, 5.76
Synonym:LB42708; LB-42708; LB 42708.
IUPAC/Chemical Name:(1-((1-(4-bromobenzyl)-1H-imidazol-5-yl)methyl)-4-(naphthalen-1-yl)-1H-pyrrol-3-yl)(morpholino)methanone
InChi Key:GUUIRIMAQGOLHT-UHFFFAOYSA-N
InChi Code:InChI=1S/C30H27BrN4O2/c31-24-10-8-22(9-11-24)17-35-21-32-16-25(35)18-33-19-28(27-7-3-5-23-4-1-2-6-26(23)27)29(20-33)30(36)34-12-14-37-15-13-34/h1-11,16,19-21H,12-15,17-18H2
SMILES Code:O=C(C1=CN(CC2=CN=CN2CC3=CC=C(Br)C=C3)C=C1C4=C5C=CC=CC5=CC=C4)N6CCOCC6
Technical Data
Additional Information
References
1: Moorthy NS, Sousa SF, Ramos MJ, Fernandes PA.Farnesyltransferase inhibitors: a comprehensive review based onquantitative structural analysis. Curr Med Chem. 2013;20(38):4888-923.PubMed PMID: 24059235.
2: Kim CK, Choi YK, Lee H, Ha KS, Won MH, Kwon YG, Kim YM. Thefarnesyltransferase inhibitor LB42708 suppresses vascular endothelialgrowth factor-induced angiogenesis by inhibiting ras-dependent mitogen-activatedprotein kinase and phosphatidylinositol 3-kinase/Akt signal pathways.Mol Pharmacol. 2010 Jul;78(1):142-50. doi: 10.1124/mol.110.063586. Epub2010 Apr 20. PubMed PMID: 20406854.
3: Kim HS, Kim JW, Gang J, Wen J, Koh SS, Koh JS, Chung HH, Song SY. Thefarnesyltransferase inhibitor, LB42708, inhibits growth and inducesapoptosis irreversibly in H-ras and K-ras-transformed rat intestinalepithelial cells. Toxicol Appl Pharmacol. 2006 Sep 15;215(3):317-29.Epub 2006 May 19. PubMed PMID: 16712893.
4: Na HJ, Lee SJ, Kang YC, Cho YL, Nam WD, Kim PK, Ha KS, Chung HT, LeeH, Kwon YG, Koh JS, Kim YM. Inhibition of farnesyltransferase preventscollagen-induced arthritis by down-regulation of inflammatory geneexpression through suppression of p21(ras)-dependent NF-kappaBactivation. J Immunol. 2004 Jul 15;173(2):1276-83. PubMed PMID:15240720.
5: Kim KW, Chung HH, Chung CW, Kim IK, Miura M, Wang S, Zhu H, Moon KD,Rha GB, Park JH, Jo DG, Woo HN, Song YH, Kim BJ, Yuan J, Jung YK.Inactivation of farnesyltransferase and geranylgeranyltransferase I bycaspase-3: cleavage of the common alpha subunit during apoptosis.Oncogene. 2001 Jan 18;20(3):358-66. PubMed PMID: 11313965.
我国旅美科学家陈清奇博士创立的MedKoo美帝药库医药公司目前正在建立全球第一个小分子抗癌药库。 MedKoo是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司。 业务范围 为全球所有从事抗癌药物研究和开发的制药公司，高校，研究院所，政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。 技术核心 以药物化学合成技术为核心，密切结合全球抗癌新药研发领域中的新技术、新理论、新趋势和新的发展方向，不断推出抗癌化合物新品种。 建造目标 MedKoo美帝药库的目标是：建成全球最大的小分子抗癌药库 ，品种最多最全、质量最好最可靠。美帝药库的宗旨是：客户第一；质量第一；信誉第一；创新第一。
